Current List of HHS-Certified Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies, 44813-44815 [2014-18135]
Download as PDF
<![CDATA[
Federal Register / Vol. 79, No. 148 / Friday, August 1, 2014 / Notices
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS).
Dated: July 28, 2014.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2014–18068 Filed 7–31–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meeting
tkelley on DSK3SPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Genetics,
Metabolomics Biochemistry of Mental and
Neurologic Disorders.
Date: August 8, 2014.
Time: 2:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Suzan Nadi, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5217B,
MSC 7846, Bethesda, MD 20892, 301–435–
1259, nadis@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS).
Dated: July 23, 2014.
Carolyn A. Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2014–18072 Filed 7–31–14; 8:45 am]
BILLING CODE 4140–01–P
VerDate Mar<15>2010
22:09 Jul 31, 2014
Jkt 232001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR13–309:
Translational Research in Pediatric and
Obstetric Pharmacology and Therapeutics.
Date: August 7, 2014.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Nancy Sheard, SCD.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6046–E,
MSC 7892, Bethesda, MD 20892, 301–408–
9901, sheardn@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Channels
and Receptors.
Date: August 8, 2014.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Peter B Guthrie, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4142,
MSC 7850, Bethesda, MD 20892, (301) 435–
1239, guthriep@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS).
PO 00000
Frm 00076
Fmt 4703
Sfmt 4703
44813
Dated: July 28, 2014.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2014–18069 Filed 7–31–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Current List of HHS-Certified
Laboratories and Instrumented Initial
Testing Facilities Which Meet Minimum
Standards To Engage in Urine Drug
Testing for Federal Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
The Department of Health and
Human Services (HHS) notifies federal
agencies of the laboratories and
Instrumented Initial Testing Facilities
(IITF) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines). The
Mandatory Guidelines were first
published in the Federal Register on
April 11, 1988 (53 FR 11970), and
subsequently revised in the Federal
Register on June 9, 1994 (59 FR 29908);
September 30, 1997 (62 FR 51118);
April 13, 2004 (69 FR 19644); November
25, 2008 (73 FR 71858); December 10,
2008 (73 FR 75122); and on April 30,
2010 (75 FR 22809).
A notice listing all currently HHScertified laboratories and IITFs is
published in the Federal Register
during the first week of each month. If
any laboratory or IITF certification is
suspended or revoked, the laboratory or
IITF will be omitted from subsequent
lists until such time as it is restored to
full certification under the Mandatory
Guidelines.
If any laboratory or IITF has
withdrawn from the HHS National
Laboratory Certification Program (NLCP)
during the past month, it will be listed
at the end and will be omitted from the
monthly listing thereafter.
This notice is also available on the
Internet at https://
www.workplace.samhsa.gov.
FOR FURTHER INFORMATION CONTACT:
Giselle Hersh, Division of Workplace
Programs, SAMHSA/CSAP, Room
7–1051, One Choke Cherry Road,
Rockville, Maryland 20857; 240–276–
2600 (voice), 240–276–2610 (fax).
SUPPLEMENTARY INFORMATION: The
Mandatory Guidelines were initially
SUMMARY:
E:\FR\FM\01AUN1.SGM
01AUN1
44814
Federal Register / Vol. 79, No. 148 / Friday, August 1, 2014 / Notices
developed in accordance with Executive
Order 12564 and section 503 of Public
Law 100–71. The ‘‘Mandatory
Guidelines for Federal Workplace Drug
Testing Programs,’’ as amended in the
revisions listed above, requires strict
standards that laboratories and IITFs
must meet in order to conduct drug and
specimen validity tests on urine
specimens for federal agencies.
To become certified, an applicant
laboratory or IITF must undergo three
rounds of performance testing plus an
on-site inspection. To maintain that
certification, a laboratory or IITF must
participate in a quarterly performance
testing program plus undergo periodic,
on-site inspections.
Laboratories and IITFs in the
applicant stage of certification are not to
be considered as meeting the minimum
requirements described in the HHS
Mandatory Guidelines. A HHS-certified
laboratory or IITF must have its letter of
certification from HHS/SAMHSA
(formerly: HHS/NIDA), which attests
that it has met minimum standards.
In accordance with the Mandatory
Guidelines dated November 25, 2008
(73 FR 71858), the following HHScertified laboratories and IITFs meet the
minimum standards to conduct drug
and specimen validity tests on urine
specimens:
HHS-Certified Instrumented Initial
Testing Facilities
Gamma-Dynacare Medical Laboratories,
6628 50th Street NW., Edmonton, AB
Canada T6B 2N7, 780–784–1190.
tkelley on DSK3SPTVN1PROD with NOTICES
HHS-Certified Laboratories
ACM Medical Laboratory, Inc., 160
Elmgrove Park, Rochester, NY 14624,
585–429–2264
Aegis Analytical Laboratories, Inc., 345
Hill Ave., Nashville, TN 37210, 615–
255–2400, (Formerly: Aegis Sciences
Corporation, Aegis Analytical
Laboratories, Inc., Aegis Analytical
Laboratories)
Alere Toxicology Services, 1111 Newton
St., Gretna, LA 70053, 504–361–8989/
800–433–3823, (Formerly: Kroll
Laboratory Specialists, Inc.,
Laboratory Specialists, Inc.)
Alere Toxicology Services, 450
Southlake Blvd., Richmond, VA
23236, 804–378–9130, (Formerly:
Kroll Laboratory Specialists, Inc.,
Scientific Testing Laboratories, Inc.;
Kroll Scientific Testing Laboratories,
Inc.)
Baptist Medical Center-Toxicology
Laboratory, 11401 I–30, Little Rock,
AR 72209–7056, 501–202–2783,
(Formerly: Forensic Toxicology
Laboratory Baptist Medical Center)
VerDate Mar<15>2010
22:09 Jul 31, 2014
Jkt 232001
Clinical Reference Lab, 8433 Quivira
Road, Lenexa, KS 66215–2802, 800–
445–6917
DrugScan, Inc., 200 Precision Road,
Suite 200, Horsham, PA 19044, 800–
235–4890
ElSohly Laboratories, Inc., 5 Industrial
Park Drive, Oxford, MS 38655, 662–
236–2609
Fortes Laboratories, Inc., 25749 SW
Canyon Creek Road, Suite 600,
Wilsonville, OR 97070, 503–486–1023
Gamma-Dynacare Medical
Laboratories*, A Division of the
Gamma-Dynacare Laboratory
Partnership, 245 Pall Mall Street,
London, ONT, Canada N6A 1P4, 519–
679–1630
Laboratory Corporation of America
Holdings, 7207 N. Gessner Road,
Houston, TX 77040, 713–856–8288/
800–800–2387
Laboratory Corporation of America
Holdings, 69 First Ave., Raritan, NJ
08869, 908–526–2400/800–437–4986,
(Formerly: Roche Biomedical
Laboratories, Inc.)
Laboratory Corporation of America
Holdings, 1904 Alexander Drive,
Research Triangle Park, NC 27709,
919–572–6900/800–833–3984,
(Formerly: LabCorp Occupational
Testing Services, Inc., CompuChem
Laboratories, Inc.; CompuChem
Laboratories, Inc., A Subsidiary of
Roche Biomedical Laboratory; Roche
CompuChem Laboratories, Inc., A
Member of the Roche Group)
Laboratory Corporation of America
Holdings, 1120 Main Street,
Southaven, MS 38671, 866–827–8042/
800–233–6339, (Formerly: LabCorp
Occupational Testing Services, Inc.;
MedExpress/National Laboratory
Center)
LabOne, Inc. d/b/a Quest Diagnostics,
10101 Renner Blvd., Lenexa, KS
66219, 913–888–3927/800–873–8845,
(Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center for
Laboratory Services, a Division of
LabOne, Inc.)
MedTox Laboratories, Inc., 402 W.
County Road D, St. Paul, MN 55112,
651–636–7466/800–832–3244
MetroLab-Legacy Laboratory Services,
1225 NE 2nd Ave., Portland, OR
97232, 503–413–5295/800–950–5295
Minneapolis Veterans Affairs Medical
Center, Forensic Toxicology
Laboratory, 1 Veterans Drive,
Minneapolis, MN 55417, 612–725–
2088
National Toxicology Laboratories, Inc.,
1100 California Ave., Bakersfield, CA
93304, 661–322–4250/800–350–3515
One Source Toxicology Laboratory, Inc.,
1213 Genoa-Red Bluff, Pasadena, TX
77504, 888–747–3774, (Formerly:
PO 00000
Frm 00077
Fmt 4703
Sfmt 4703
University of Texas Medical Branch,
Clinical Chemistry Division; UTMB
Pathology-Toxicology Laboratory)
Pacific Toxicology Laboratories, 9348
DeSoto Ave., Chatsworth, CA 91311,
800–328–6942, (Formerly: Centinela
Hospital Airport Toxicology
Laboratory)
Pathology Associates Medical
Laboratories, 110 West Cliff Dr.,
Spokane, WA 99204, 509–755–8991/
800–541–7891x7
Phamatech, Inc., 10151 Barnes Canyon
Road, San Diego, CA 92121, 858–643–
5555
Quest Diagnostics Incorporated, 1777
Montreal Circle, Tucker, GA 30084,
800–729–6432, (Formerly: SmithKline
Beecham Clinical Laboratories;
SmithKline Bio-Science Laboratories)
Quest Diagnostics Incorporated, 400
Egypt Road, Norristown, PA 19403,
610–631–4600/877–642–2216,
(Formerly: SmithKline Beecham
Clinical Laboratories; SmithKline BioScience Laboratories)
Quest Diagnostics Incorporated, 8401
Fallbrook Ave., West Hills, CA 91304,
818–737–6370, (Formerly: SmithKline
Beecham Clinical Laboratories)
Redwood Toxicology Laboratory,
3700650 Westwind Blvd., Santa Rosa,
CA 95403, 800–255–2159
Southwest Laboratories, 4625 E. Cotton
Center Boulevard, Suite 177, Phoenix,
AZ 85040, 602–438–8507/800–279–
0027
STERLING Reference Laboratories, 2617
East L Street, Tacoma, Washington
98421, 800–442–0438
U.S. Army Forensic Toxicology Drug
Testing Laboratory, 2490 Wilson St.,
Fort George G. Meade, MD 20755–
5235, 301–677–7085
* The Standards Council of Canada
(SCC) voted to end its Laboratory
Accreditation Program for Substance
Abuse (LAPSA) effective May 12, 1998.
Laboratories certified through that
program were accredited to conduct
forensic urine drug testing as required
by U.S. Department of Transportation
(DOT) regulations. As of that date, the
certification of those accredited
Canadian laboratories will continue
under DOT authority. The responsibility
for conducting quarterly performance
testing plus periodic on-site inspections
of those LAPSA-accredited laboratories
was transferred to the U.S. HHS, with
the HHS’ NLCP contractor continuing to
have an active role in the performance
testing and laboratory inspection
processes. Other Canadian laboratories
wishing to be considered for the NLCP
may apply directly to the NLCP
contractor just as U.S. laboratories do.
Upon finding a Canadian laboratory to
be qualified, HHS will recommend that
E:\FR\FM\01AUN1.SGM
01AUN1
Federal Register / Vol. 79, No. 148 / Friday, August 1, 2014 / Notices
DOT certify the laboratory (Federal
Register, July 16, 1996) as meeting the
minimum standards of the Mandatory
Guidelines published in the Federal
Register on April 30, 2010 (75 FR
22809). After receiving DOT
certification, the laboratory will be
included in the monthly list of HHScertified laboratories and participate in
the NLCP certification maintenance
program.
Janine Denis Cook,
Chemist, Division of Workplace Programs,
Center for Substance Abuse Prevention,
SAMHSA.
[FR Doc. 2014–18135 Filed 7–31–14; 8:45 am]
BILLING CODE 4160–20–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
tkelley on DSK3SPTVN1PROD with NOTICES
Notice of Meeting
Pursuant to Public Law 92–463,
notice is hereby given of the combined
meeting on August 27, 2014, of the
Substance Abuse and Mental Health
Services Administration’s (SAMHSA)
four National Advisory Councils (the
SAMHSA National Advisory Council
(NAC), the Center for Mental Health
Services NAC, the Center for Substance
Abuse Prevention NAC, the Center for
Substance Abuse Treatment NAC), and
the two SAMHSA Advisory Committees
(Advisory Committee for Women’s
Services, and the Tribal Technical
Advisory Committee).
The Councils were established to
advise the Secretary, Department of
Health and Human Services (HHS), the
Administrator, SAMHSA, and Center
Directors, concerning matters relating to
the activities carried out by and through
the Centers and the policies respecting
such activities.
Under Section 501 of the Public
Health Service Act, the Advisory
Committee for Women’s Services
(ACWS) is statutorily mandated to
advise the SAMHSA Administrator and
the Associate Administrator for
Women’s Services on appropriate
activities to be undertaken by SAMHSA
and its Centers with respect to women’s
substance abuse and mental health
services.
Pursuant to Presidential Executive
Order No. 13175, November 6, 2000,
and the Presidential Memorandum of
September 23, 2004, SAMHSA
established the Tribal Technical
Advisory Committee (TTAC) for
working with Federally-recognized
Tribes to enhance the government-to-
VerDate Mar<15>2010
22:09 Jul 31, 2014
Jkt 232001
government relationship, honor Federal
trust responsibilities and obligations to
Tribes and American Indian and Alaska
Natives. The SAMHSA TTAC serves as
an advisory body to SAMHSA.
The August 27 combined meeting will
include a report from the SAMHSA
Administrator, an update and
discussion regarding Military members
returning home and their families.
The meeting is open to the public and
will be held online via Chorus Call and
teleconference. Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions should be forwarded to the
contact person on or before August 18,
2014. Oral presentations from the public
will be scheduled at the conclusion of
the meeting. Individuals interested in
making oral presentations are
encouraged to notify the contact on or
before August 18, 2014. Five minutes
will be allotted for each presentation.
Substantive program information may
be obtained after the meeting by
accessing the SAMHSA Committee Web
site, https://nac.samhsa.gov/, or by
contacting Ms. Wood.
Committee Names: Substance Abuse
and Mental Health Services
Administration National Advisory
Council; Center for Mental Health
Services National Advisory; Council
Center for Substance Abuse Prevention
National Advisory Council; Center for
Substance Abuse Treatment National
Advisory Council; SAMHSA’s Advisory
Committee for Women’s Services;
SAMHSA Tribal Technical Advisory
Committee.
Date/Time/Type: Wednesday, August
26, 2014, 1:00 p.m.–3:30 p.m. EDT
(OPEN).
Place: Chorus call Web cast: https://
services.choruscall.com/links/
samhsa140827.html; Call-in Number
(866) 652–5200; Passcode: SAMHSA.
Contact: Geretta Wood, Committee
Management Officer and Designated
Federal Official, SAMHSA National
Advisory Council, SAMHSA’s Advisory
Committee for Women’s Services,
1 Choke Cherry Road, Rockville,
Maryland 20857, Telephone: (240) 276–
2326, Fax: (240) 276–2253 and Email:
geretta.wood@samhsa.hhs.gov.
Cathy J. Friedman,
Public Health Analyst, SAMHSA.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
National Advisory Committee Notice of
Meeting
Pursuant to Public Law 92–463,
notice is hereby given of the meeting on
of the Substance Abuse and Mental
Health Services Administration’s
(SAMHSA) National Advisory
Committee on August 28, 2014.
The meeting will include an update
from the SAMHSA Administrator and
discussions regarding Healthcare and
Parity Implementation.
The meeting is open to the public and
will be held online via Microsoft Office
2007 Live Meeting. Interested persons
may present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions should be forwarded to the
contact person on or before August 18,
2014. Oral presentations from the public
will be scheduled at the conclusion of
the meeting. Individuals interested in
making oral presentations are
encouraged to notify the contact on or
before August 18, 2014. Five minutes
will be allotted for each presentation.
Substantive program information may
be obtained after the meeting by
accessing the SAMHSA Committee Web
site, https://nac.samhsa.gov/, or by
contacting Geretta P. Wood.
Committee Name: Substance Abuse and
Mental Health Services Administration
National Advisory Committee (NAC)
Date/Time/Type: August 28, 2014 from
1:00 p.m. to 4:00 p.m. EDT: (OPEN)
Place: Live meeting webcast: https://
www.mymeetings.com/nc/
join.php?i=PW7187982&
p=AMHSA%20NAC&t=c.
Conference number: PW7187982.
Audience passcode: SAMHSA NAC.
Dial in number: 888–968–4347.
Contact: Geretta Wood, Committee
Management Officer and Designated Federal
Official, SAMHSA National Advisory
Council, SAMHSA’s Advisory Committee for
Women’s Services, 1 Choke Cherry Road,
Rockville, Maryland 20857, Telephone: (240)
276–2326, Fax: (240) 276–2253 and Email:
geretta.wood@samhsa.hhs.gov.
Cathy J. Friedman,
Public Health Analyst, SAMHSA.
[FR Doc. 2014–18161 Filed 7–31–14; 8:45 am]
[FR Doc. 2014–18166 Filed 7–31–14; 8:45 am]
BILLING CODE 4162–20–P
BILLING CODE 4162–20–P
PO 00000
Frm 00078
Fmt 4703
Sfmt 9990
44815
E:\FR\FM\01AUN1.SGM
01AUN1
]]>Agencies
[Federal Register Volume 79, Number 148 (Friday, August 1, 2014)]
[Notices]
[Pages 44813-44815]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-18135]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Current List of HHS-Certified Laboratories and Instrumented
Initial Testing Facilities Which Meet Minimum Standards To Engage in
Urine Drug Testing for Federal Agencies
AGENCY: Substance Abuse and Mental Health Services Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Department of Health and Human Services (HHS) notifies
federal agencies of the laboratories and Instrumented Initial Testing
Facilities (IITF) currently certified to meet the standards of the
Mandatory Guidelines for Federal Workplace Drug Testing Programs
(Mandatory Guidelines). The Mandatory Guidelines were first published
in the Federal Register on April 11, 1988 (53 FR 11970), and
subsequently revised in the Federal Register on June 9, 1994 (59 FR
29908); September 30, 1997 (62 FR 51118); April 13, 2004 (69 FR 19644);
November 25, 2008 (73 FR 71858); December 10, 2008 (73 FR 75122); and
on April 30, 2010 (75 FR 22809).
A notice listing all currently HHS-certified laboratories and IITFs
is published in the Federal Register during the first week of each
month. If any laboratory or IITF certification is suspended or revoked,
the laboratory or IITF will be omitted from subsequent lists until such
time as it is restored to full certification under the Mandatory
Guidelines.
If any laboratory or IITF has withdrawn from the HHS National
Laboratory Certification Program (NLCP) during the past month, it will
be listed at the end and will be omitted from the monthly listing
thereafter.
This notice is also available on the Internet at https://www.workplace.samhsa.gov.
FOR FURTHER INFORMATION CONTACT: Giselle Hersh, Division of Workplace
Programs, SAMHSA/CSAP, Room 7-1051, One Choke Cherry Road, Rockville,
Maryland 20857; 240-276-2600 (voice), 240-276-2610 (fax).
SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were initially
[[Page 44814]]
developed in accordance with Executive Order 12564 and section 503 of
Public Law 100-71. The ``Mandatory Guidelines for Federal Workplace
Drug Testing Programs,'' as amended in the revisions listed above,
requires strict standards that laboratories and IITFs must meet in
order to conduct drug and specimen validity tests on urine specimens
for federal agencies.
To become certified, an applicant laboratory or IITF must undergo
three rounds of performance testing plus an on-site inspection. To
maintain that certification, a laboratory or IITF must participate in a
quarterly performance testing program plus undergo periodic, on-site
inspections.
Laboratories and IITFs in the applicant stage of certification are
not to be considered as meeting the minimum requirements described in
the HHS Mandatory Guidelines. A HHS-certified laboratory or IITF must
have its letter of certification from HHS/SAMHSA (formerly: HHS/NIDA),
which attests that it has met minimum standards.
In accordance with the Mandatory Guidelines dated November 25, 2008
(73 FR 71858), the following HHS-certified laboratories and IITFs meet
the minimum standards to conduct drug and specimen validity tests on
urine specimens:
HHS-Certified Instrumented Initial Testing Facilities
Gamma-Dynacare Medical Laboratories, 6628 50th Street NW., Edmonton, AB
Canada T6B 2N7, 780-784-1190.
HHS-Certified Laboratories
ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY 14624,
585-429-2264
Aegis Analytical Laboratories, Inc., 345 Hill Ave., Nashville, TN
37210, 615-255-2400, (Formerly: Aegis Sciences Corporation, Aegis
Analytical Laboratories, Inc., Aegis Analytical Laboratories)
Alere Toxicology Services, 1111 Newton St., Gretna, LA 70053, 504-361-
8989/800-433-3823, (Formerly: Kroll Laboratory Specialists, Inc.,
Laboratory Specialists, Inc.)
Alere Toxicology Services, 450 Southlake Blvd., Richmond, VA 23236,
804-378-9130, (Formerly: Kroll Laboratory Specialists, Inc., Scientific
Testing Laboratories, Inc.; Kroll Scientific Testing Laboratories,
Inc.)
Baptist Medical Center-Toxicology Laboratory, 11401 I-30, Little Rock,
AR 72209-7056, 501-202-2783, (Formerly: Forensic Toxicology Laboratory
Baptist Medical Center)
Clinical Reference Lab, 8433 Quivira Road, Lenexa, KS 66215-2802, 800-
445-6917
DrugScan, Inc., 200 Precision Road, Suite 200, Horsham, PA 19044, 800-
235-4890
ElSohly Laboratories, Inc., 5 Industrial Park Drive, Oxford, MS 38655,
662-236-2609
Fortes Laboratories, Inc., 25749 SW Canyon Creek Road, Suite 600,
Wilsonville, OR 97070, 503-486-1023
Gamma-Dynacare Medical Laboratories*, A Division of the Gamma-Dynacare
Laboratory Partnership, 245 Pall Mall Street, London, ONT, Canada N6A
1P4, 519-679-1630
Laboratory Corporation of America Holdings, 7207 N. Gessner Road,
Houston, TX 77040, 713-856-8288/800-800-2387
Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ
08869, 908-526-2400/800-437-4986, (Formerly: Roche Biomedical
Laboratories, Inc.)
Laboratory Corporation of America Holdings, 1904 Alexander Drive,
Research Triangle Park, NC 27709, 919-572-6900/800-833-3984, (Formerly:
LabCorp Occupational Testing Services, Inc., CompuChem Laboratories,
Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical
Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche
Group)
Laboratory Corporation of America Holdings, 1120 Main Street,
Southaven, MS 38671, 866-827-8042/800-233-6339, (Formerly: LabCorp
Occupational Testing Services, Inc.; MedExpress/National Laboratory
Center)
LabOne, Inc. d/b/a Quest Diagnostics, 10101 Renner Blvd., Lenexa, KS
66219, 913-888-3927/800-873-8845, (Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center for Laboratory Services, a Division
of LabOne, Inc.)
MedTox Laboratories, Inc., 402 W. County Road D, St. Paul, MN 55112,
651-636-7466/800-832-3244
MetroLab-Legacy Laboratory Services, 1225 NE 2nd Ave., Portland, OR
97232, 503-413-5295/800-950-5295
Minneapolis Veterans Affairs Medical Center, Forensic Toxicology
Laboratory, 1 Veterans Drive, Minneapolis, MN 55417, 612-725-2088
National Toxicology Laboratories, Inc., 1100 California Ave.,
Bakersfield, CA 93304, 661-322-4250/800-350-3515
One Source Toxicology Laboratory, Inc., 1213 Genoa-Red Bluff, Pasadena,
TX 77504, 888-747-3774, (Formerly: University of Texas Medical Branch,
Clinical Chemistry Division; UTMB Pathology-Toxicology Laboratory)
Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA
91311, 800-328-6942, (Formerly: Centinela Hospital Airport Toxicology
Laboratory)
Pathology Associates Medical Laboratories, 110 West Cliff Dr., Spokane,
WA 99204, 509-755-8991/800-541-7891x7
Phamatech, Inc., 10151 Barnes Canyon Road, San Diego, CA 92121, 858-
643-5555
Quest Diagnostics Incorporated, 1777 Montreal Circle, Tucker, GA 30084,
800-729-6432, (Formerly: SmithKline Beecham Clinical Laboratories;
SmithKline Bio-Science Laboratories)
Quest Diagnostics Incorporated, 400 Egypt Road, Norristown, PA 19403,
610-631-4600/877-642-2216, (Formerly: SmithKline Beecham Clinical
Laboratories; SmithKline Bio-Science Laboratories)
Quest Diagnostics Incorporated, 8401 Fallbrook Ave., West Hills, CA
91304, 818-737-6370, (Formerly: SmithKline Beecham Clinical
Laboratories)
Redwood Toxicology Laboratory, 3700650 Westwind Blvd., Santa Rosa, CA
95403, 800-255-2159
Southwest Laboratories, 4625 E. Cotton Center Boulevard, Suite 177,
Phoenix, AZ 85040, 602-438-8507/800-279-0027
STERLING Reference Laboratories, 2617 East L Street, Tacoma, Washington
98421, 800-442-0438
U.S. Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson St.,
Fort George G. Meade, MD 20755-5235, 301-677-7085
* The Standards Council of Canada (SCC) voted to end its Laboratory
Accreditation Program for Substance Abuse (LAPSA) effective May 12,
1998. Laboratories certified through that program were accredited to
conduct forensic urine drug testing as required by U.S. Department of
Transportation (DOT) regulations. As of that date, the certification of
those accredited Canadian laboratories will continue under DOT
authority. The responsibility for conducting quarterly performance
testing plus periodic on-site inspections of those LAPSA-accredited
laboratories was transferred to the U.S. HHS, with the HHS' NLCP
contractor continuing to have an active role in the performance testing
and laboratory inspection processes. Other Canadian laboratories
wishing to be considered for the NLCP may apply directly to the NLCP
contractor just as U.S. laboratories do.
Upon finding a Canadian laboratory to be qualified, HHS will
recommend that
[[Page 44815]]
DOT certify the laboratory (Federal Register, July 16, 1996) as meeting
the minimum standards of the Mandatory Guidelines published in the
Federal Register on April 30, 2010 (75 FR 22809). After receiving DOT
certification, the laboratory will be included in the monthly list of
HHS-certified laboratories and participate in the NLCP certification
maintenance program.
Janine Denis Cook,
Chemist, Division of Workplace Programs, Center for Substance Abuse
Prevention, SAMHSA.
[FR Doc. 2014-18135 Filed 7-31-14; 8:45 am]
BILLING CODE 4160-20-P
